Business Services

Atreca

$15.09
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.19 (+1.28%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Atreca and other stocks, options, and ETFs commission-free!

About BCEL

Atreca, Inc. Class A Common Stock, also called Atreca, is a biopharmaceutical company. It develops novel therapeutics and immunotherapies based on a deep understanding of the human immune response. Its technology leverages next-generation sequencing to identify the set of functional antibodies produced in patients during an immune response. The company was founded by Robert Axtell, Guy Cavet, Jeremy Sokolove, Tito A. Serafini, Paulette A. Dillon, Daniel Emerling, Wayne Volkmuth, Jonathan Woo, Yann Chong Tan, William H. Robinson and Lawrence J. Steinman on June 11, 2010 and is headquartered in South San Francisco, CA. The listed name for BCEL is Atreca, Inc. Class A Common Stock.

CEO
John A. Orwin
Employees
113
Headquarters
South San Francisco, California
Founded
2010
Market Cap
585.50M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
184.80K
High Today
$15.22
Low Today
$14.38
Open Price
$14.91
Volume
273.36K
52 Week High
$29.35
52 Week Low
$10.88

Collections

BCEL Earnings

-$3.67
-$2.45
-$1.22
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 11, Pre-Market

You May Also Like

WTRE
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure